Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Detalles Bibliográficos
Autores principales: Link-Gelles, Ruth, Levy, Matthew E., Gaglani, Manjusha, Irving, Stephanie A., Stockwell, Melissa, Dascomb, Kristin, DeSilva, Malini B., Reese, Sarah E., Liao, I-Chia, Ong, Toan C., Grannis, Shaun J., McEvoy, Charlene, Patel, Palak, Klein, Nicola P., Hartmann, Emily, Stenehjem, Edward, Natarajan, Karthik, Naleway, Allison L., Murthy, Kempapura, Rao, Suchitra, Dixon, Brian E., Kharbanda, Anupam B., Akinseye, Akintunde, Dickerson, Monica, Lewis, Ned, Grisel, Nancy, Han, Jungmi, Barron, Michelle A., Fadel, William F., Dunne, Margaret M., Goddard, Kristin, Arndorfer, Julie, Konatham, Deepika, Valvi, Nimish R., Currey, J. C., Fireman, Bruce, Raiyani, Chandni, Zerbo, Ousseny, Sloan-Aagard, Chantel, Ball, Sarah W., Thompson, Mark G., Tenforde, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Full Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310634/
https://www.ncbi.nlm.nih.gov/pubmed/35862287
http://dx.doi.org/10.15585/mmwr.mm7129e1

Ejemplares similares

Ejemplares similares